OMICS 2.0: An Accelerator for Global Science,Systems Medicine and Responsible Innovation

Birch K , and Tyfield D . (2013). Theorizing the bioeconomy: Biovalue, biocapital, bioeconomics or … what?. Sci Technol Human Values, 38, 299–327.

Dandara C , Huzair F , Borda-Rodriguez A , Chirikure S , Okpechi I , Warnich L , and Masimirembwa C . (2014). H3Africa and the African life sciences ecosystem: Building sustainable innovation. OMICS, 18, 733–739.

Dove ES , and Özdemir V . (2015). What role for law, human rights, and bioethics in an age of big data, consortia science, and consortia ethics? The importance of trustworthiness. Laws, 4, 515–540. Available from: http://www.mdpi.com/2075-471X/4/3/515#stats. Accessed September 2, 2015.

ElRakaiby M , Dutilh BE , Rizkallah MR , Boleij A , Cole JN , and Aziz RK . (2014). Pharmacomicrobiomics: The impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS, 18, 402–414.

Funtowicz SO , and Ravetz JR . (1993). Science for the post-normal age. Futures, 25, 735–755.

Guston DH . (2015). Responsible innovation: Who could be against that?. J Responsible Innovation, 2, 1–4.

Kickbusch I . (2015). The political determinants of health—10 years on. BMJ, 350, h81.

Latour B . (2001). “Réponse aux objections…”. Revue du MAUSS, 17, 137–152.

Latour B . (2005). Reassembling the Social. An Introduction to Actor-Network-Theory. Oxford: Oxford University Press.

Özdemir V . (2014). Personalized medicine across disciplines and without borders. Vural Özdemir speaks to Hannah Wilson, Commissioning Editor. Per Med 11, 687–691. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481090/ Accessed September 2, 2015.

Ozdemir V , Endrenyi L , Aynacıoğlu S , et al. (2014). Bernard Lerer: Recipient of the 2014 Inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics). OMICS, 18, 211–221.

Özdemir V , Kılıç H , Yıldırım A , et al. (2015). A code of ethics for ethicists: What would Pierre Bourdieu say? “Do not misuse social capital in the age of consortia ethics.”. Am J Bioethics, 15, 64–67.

Pavlidis C , Lanara Z , Balasopoulou A , Nebel J-C , Katsila T , and Patrinos GP . (2015). Meta-analysis of genes in commercially available nutrigenomic tests denotes lack of association with dietary intake and nutrient-related pathologies. OMICS, 19, 512–520.

Rutka J , Martin J , and Kılıç T . (2014). OMICS and 21st century brain surgery from education to practice: James Rutka of the University of Toronto interviewed by Joseph B. Martin (Boston) and Türker Kılıç (İstanbul). OMICS, 18, 711–713.

Thoreau F , and Delvenne P . (2012). Have STS fallen into a political void? Depoliticisation and engagement in the case of nanotechnologies. Politica Sociedade, 11, 205–226.

van Oudheusden M . (2014). Where are the politics in responsible innovation? European governance, technology assessments, and beyond. J Responsible Innovation, 1: 67–86.

Vayena E . (2014). The next step in the patient revolution: Patients initiating and leading research. BMJ, 349, g4318.